Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

2

Revenue 2017

Revlimid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Revlimid was produced by Celgene.

CHMP backs orphan drugs Uptravi and Coagadex

CHMP backs orphan drugs Uptravi and Coagadex new indications for Celgene's multiple myeloma therapy Revlimid (lenalidomide) and Novartis' Revolade (eltrombopag) for idiopathic thrombocytopenic purpura (ITP). ... Revlimid has been backed for the treatment of adult patients with relapsed or

Empliciti on track for European approval in multiple myeloma

Empliciti on track for European approval in multiple myeloma The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Empliciti (elotuzumab) for use in combination with Celgene's Revlimid (lenalidomide) and corticosteroid drug dexamethasone as a ... The immuno-oncology drug was first

BMS' Empliciti approved by FDA for multiple myeloma

BMS' Empliciti approved by FDA for multiple myeloma time before their disease worsened (19.4 months) compared to participants taking only Revlimid and dexamethasone (14.9 months). ... All told, 78.5% of those taking the Empliciti regimen experienced a complete or partial shrinkage of their tumours

FDA clears Takeda's oral multiple myeloma drug

FDA clears Takeda's oral multiple myeloma drug Ninlaro ( ixazomib; formerly MLN9708) has been cleared for use in combination with Celgene's immunomodulatory drug Revlimid (lenalidomide) and dexamethasone in patients with the blood cancer who have been treated with

Amgen’s Kyprolis approved in Europe

Amgen’s Kyprolis approved in Europe Multiple myeloma drugwins licence three years after gaining US approval. Amgen's Kyprolis has been approved in Europe in combination with Celgene's Revlimid and dexamethasone for the treatment of adults

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics